MYCN and neuroblastoma: From a mechanistic and functional point of view, the worsening outcome of NB patients with tumors carrying both ALK mutations and MYCN amplification can be explained by promoter analysis revealing ALK as a transcriptional target of MYCN [17] Therefore, amplified/overexpressed MYCN leads to increased levels of ALK in whichever form, either wild-type or mutated.